Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6484237 | 1.00 | HTR2C (0.50) | HTR2CHTR2AHTR2BCA12CA1 | |
| SCHEMBL29474981 | 1.00 | HTR2C (0.50) | HTR2CHTR2AHTR2BCA12CA1 | |
| SCHEMBL29041073 | 0.84 | HTR2C (0.51) | HTR2CHTR2AHTR2BCA12CA1 | |
| SCHEMBL27845790 | 0.83 | TSHR (0.44) | HTR2CHTR2AHTR2BCYP19A1DRD2 | |
| SCHEMBL7786361 | 0.82 | CYP19A1 (0.49) | CYP19A1ADRA1ATSHR | |
| SCHEMBL4753995 | 0.80 | ALDH1A1 (0.41) | HTR2CHTR2AHTR2BDRD2ADRA1A | |
| SCHEMBL30949067 | 0.80 | HTR2C (0.47) | HTR2CHTR2AHTR2BDRD2MEN1 | |
| SCHEMBL11302784 | 0.79 | HTR2B (0.55) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL14945596 | 0.79 | HDAC4 (0.42) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL22994705 | 0.78 | ALDH1A1 (0.44) | HTR2CHTR2AHTR2BADRA1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4545535-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4010344-B1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3660023-B1 | THIENOPYRIMIDINEDIONE COMPOUNDS AS ACC INHIBITORS AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2023-03-08 | — | — | EP | disclosed |
| US-20230002405-A1 | ACC INHIBITOR AND USE THEREOF | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-4010344-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11352371-B2 | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352371-B2 | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3628320-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11186587-B2 | Compound as ACC inhibitor and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| EP-0654534-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-24 | — | — | EP | disclosed |
| EP-0611826-A2 | Processes for production of optically active epoxides | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-24 | — | — | EP | disclosed |
| US-5266485-A | Biosynthesis | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1993-11-30 | — | — | US | disclosed |
| EP-0493617-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE (-)-2-HALO-1-(SUBSTITUTED PHENYL)ETHANOL AND (-)-SUBSTITUTED STYRENE OXIDE | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-07-08 | — | — | EP | disclosed |
| US-4721717-A | α-(aminoalkylaminomethyl)phenylmethanols, composition containing them, and use thereof to treat certain heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1988-01-26 | — | — | US | disclosed |
| US-4321195-A | 6-Halo-7,8-dimethoxy-1-(methoxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines | SMITHKLINE CORPORATION (US) | 1982-03-23 | — | — | US | disclosed |
| US-4197297-A | 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines | SMITHKLINE CORPORATION (US) | 1980-04-08 | — | — | US | disclosed |
| US-4160765-A | Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds | SMITHKLINE CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
| US-4131686-A | ANTIDIABETIC | TANABE SEIYAKU CO., LTD. (JP) | 1978-12-26 | — | — | US | disclosed |
| US-4011319-A | STIMULATING DOPAMINE RECEPTORS, RENAL VASODILATORS, DIURETICS | SMITHKLINE CORPORATION (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | ACACA, ACACB, COASY | HTR2C 4484/4885HTR2A 4531/4885HTR2B 4661/4885 |
| US-11352371-B2 | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | ACACB, ACACA, ACAT2 | HTR2C 4221/4885HTR2A 4267/4885HTR2B 4572/4885 |
| US-20230002405-A1 | ACC INHIBITOR AND USE THEREOF | ACACA, ACACB, ACAT1 | HTR2C 4277/4885HTR2A 4393/4885HTR2B 4586/4885 |
| US-11186587-B2 | Compound as ACC inhibitor and use thereof | ACACA, ACACB, ACAT2 | HTR2C 4746/4885HTR2A 4827/4885HTR2B 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.